DBV Technologies Stock Rebounds 2% After Prolonged Decline
DBV Technologies stock moves forward in mid-session in a well-oriented Parisian market. However, the French biotech remains down for the week and below its short-term moving averages.
A Technical Rebound That Leaves the Stock Below Its 20 and 50-Day Moving Averages
Today's rebound remains modest compared to recent dynamics: the biotech has lost nearly 4% over the week and more than 10% over three months. The stock is trading 4.52% below its 20-day moving average (€3.41) and nearly 7% below its 50-day moving average (€3.50), while a Relative Strength Index (RSI) at 36 indicates selling pressure from recent sessions without having tipped into oversold territory. The technical support at €3.20 is in immediate proximity to the current price, and its behavior will dictate the continuation of the movement. On the other hand, the 200-day moving average at €2.90 provides a comfortable cushion, with the stock maintaining nearly 100% gain over the year.
Slight Increase in Short Positions
According to reviewed statements, two funds accumulate 2% of the capital sold short, up from 1.44% a month ago (+0.56 point over 30 days). This increase remains contained and does not suggest massive distrust: it simply signals that a modest fraction of the capital remains positioned for a decline, to be monitored over time rather than isolated. The underlying context remains that of a biotech with significant regulatory stakes. DBV recently confirmed two upcoming Biologics License Application (BLA) submissions planned for 2026 with the FDA for its Viaskin Peanut allergen patch, one for children aged 4 to 7 years and the other for ages 1 to 3, as indicated in early May. At that time, the company had $229 million in cash reserves, sufficient to last until the second quarter of 2027. Next statutory meeting: the general assembly on June 3.
